{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T18:49:48Z","timestamp":1787251788882,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-024-02447-7","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T05:02:09Z","timestamp":1727931729000},"page":"333-344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Spliceosome component TCERG1 regulates the aggressiveness of somatotroph adenoma"],"prefix":"10.1007","volume":"48","author":[{"given":"Kyungwon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ju","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Cheol","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngsook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hyung","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Jig","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5822-5235","authenticated-orcid":false,"given":"Chan Woo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8693-9630","authenticated-orcid":false,"given":"Cheol Ryong","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"2447_CR1","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1056\/NEJMra062453","volume":"355","author":"S Melmed","year":"2006","unstructured":"Melmed S (2006) Acromegaly. N Engl J Med 355:2558\u20132573. https:\/\/doi.org\/10.1056\/NEJMra062453","journal-title":"N Engl J Med"},{"key":"2447_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.20945\/2359-3997000000193","volume":"63","author":"L Kasuki","year":"2020","unstructured":"Kasuki L, Rocha PdaS, Lamback EB, Gadelha MR (2020) Determinants of morbidities and mortality in acromegaly. Arch Endocrinol Metab 63:630\u2013637. https:\/\/doi.org\/10.20945\/2359-3997000000193","journal-title":"Arch Endocrinol Metab"},{"key":"2447_CR3","doi-asserted-by":"publisher","first-page":"101264","DOI":"10.1016\/j.beem.2019.02.001","volume":"33","author":"L Maione","year":"2019","unstructured":"Maione L, Chanson P (2019) National acromegaly registries. Best Pract Res Clin Endocrinol Metab 33:101264. https:\/\/doi.org\/10.1016\/j.beem.2019.02.001","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2447_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","volume":"40","author":"MR Gadelha","year":"2019","unstructured":"Gadelha MR, Kasuki L, Lim DST, Fleseriu M (2019) Systemic complications of Acromegaly and the impact of the Current Treatment Landscape: an update. Endocr Rev 40:268\u2013332. https:\/\/doi.org\/10.1210\/er.2018-00115","journal-title":"Endocr Rev"},{"key":"2447_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrm.2017.27","volume":"18","author":"FE Baralle","year":"2017","unstructured":"Baralle FE, Giudice J (2017) Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol 18:437\u2013451. https:\/\/doi.org\/10.1038\/nrm.2017.27","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2447_CR6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/nature07509","volume":"456","author":"ET Wang","year":"2008","unstructured":"Wang ET, Sandberg R, Luo S et al (2008) Alternative isoform regulation in human tissue transcriptomes. Nature 456:470\u2013476. https:\/\/doi.org\/10.1038\/nature07509","journal-title":"Nature"},{"key":"2447_CR7","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1038\/s41388-019-1138-2","volume":"39","author":"X Dong","year":"2020","unstructured":"Dong X, Chen R (2020) Understanding aberrant RNA splicing to facilitate cancer diagnosis and therapy. Oncogene 39:2231\u20132242. https:\/\/doi.org\/10.1038\/s41388-019-1138-2","journal-title":"Oncogene"},{"key":"2447_CR8","doi-asserted-by":"publisher","first-page":"7647","DOI":"10.1158\/0008-5472.CAN-04-1910","volume":"64","author":"JP Venables","year":"2004","unstructured":"Venables JP (2004) Aberrant and alternative splicing in Cancer. Cancer Res 64:7647\u20137654. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1910","journal-title":"Cancer Res"},{"key":"2447_CR9","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nchembio0907-533","volume":"3","author":"B Rymond","year":"2007","unstructured":"Rymond B (2007) Targeting the spliceosome. Nat Chem Biol 3:533\u2013535. https:\/\/doi.org\/10.1038\/nchembio0907-533","journal-title":"Nat Chem Biol"},{"key":"2447_CR10","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nchembio.2007.16","volume":"3","author":"Y Kotake","year":"2007","unstructured":"Kotake Y, Sagane K, Owa T et al (2007) Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol 3:570\u2013575. https:\/\/doi.org\/10.1038\/nchembio.2007.16","journal-title":"Nat Chem Biol"},{"key":"2447_CR11","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.3390\/cancers11101439","volume":"11","author":"MC V\u00e1zquez-Borrego","year":"2019","unstructured":"V\u00e1zquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E et al (2019) Splicing Machinery is dysregulated in Pituitary neuroendocrine tumors and is Associated with aggressiveness features. Cancers 11:1439. https:\/\/doi.org\/10.3390\/cancers11101439","journal-title":"Cancers"},{"key":"2447_CR12","doi-asserted-by":"publisher","first-page":"10328","DOI":"10.3390\/ijms221910328","volume":"22","author":"L Pastorino","year":"2021","unstructured":"Pastorino L, Grillo F, Albertelli M et al (2021) Insights into mechanisms of Tumorigenesis in Neuroendocrine neoplasms. Int J Mol Sci 22:10328. https:\/\/doi.org\/10.3390\/ijms221910328","journal-title":"Int J Mol Sci"},{"key":"2447_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","volume":"33","author":"SL Asa","year":"2022","unstructured":"Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO classification of Pituitary tumors. Endocr Pathol 33:6\u201326. https:\/\/doi.org\/10.1007\/s12022-022-09703-7","journal-title":"Endocr Pathol"},{"key":"2447_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1530\/EJE-21-1094","volume":"186","author":"J Kim","year":"2022","unstructured":"Kim J, Hwang Y, Park YW et al (2022) Revisiting growth hormone nadir cut-offs for remission in patients with acromegaly. Eur J Endocrinol 186:657\u2013665. https:\/\/doi.org\/10.1530\/EJE-21-1094","journal-title":"Eur J Endocrinol"},{"key":"2447_CR15","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1227\/00006123-199310000-00008","volume":"33","author":"E Knosp","year":"1993","unstructured":"Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610\u2013617 discussion 617\u2013618. https:\/\/doi.org\/10.1227\/00006123-199310000-00008","journal-title":"Neurosurgery"},{"key":"2447_CR16","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1038\/s41467-020-18500-x","volume":"11","author":"D Abboud","year":"2020","unstructured":"Abboud D, Daly AF, Dupuis N et al (2020) GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq\/11. Nat Commun 11:4752. https:\/\/doi.org\/10.1038\/s41467-020-18500-x","journal-title":"Nat Commun"},{"key":"2447_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1530\/EJE-16-0620","volume":"176","author":"E Ritvonen","year":"2017","unstructured":"Ritvonen E, Pitk\u00e4nen E, Karppinen A et al (2017) Impact of AIP and inhibitory G protein alpha 2 proteins on clinical features of sporadic GH-secreting pituitary adenomas. Eur J Endocrinol 176:243\u2013252. https:\/\/doi.org\/10.1530\/EJE-16-0620","journal-title":"Eur J Endocrinol"},{"key":"2447_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1530\/EJE-15-1064","volume":"174","author":"CL Ronchi","year":"2016","unstructured":"Ronchi CL, Peverelli E, Herterich S et al (2016) Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. Eur J Endocrinol 174:363\u2013372. https:\/\/doi.org\/10.1530\/EJE-15-1064","journal-title":"Eur J Endocrinol"},{"key":"2447_CR19","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.1172\/JCI138540","volume":"130","author":"A Ben-Shlomo","year":"2020","unstructured":"Ben-Shlomo A, Deng N, Ding E et al (2020) DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. J Clin Invest 130:5738\u20135755. https:\/\/doi.org\/10.1172\/JCI138540","journal-title":"J Clin Invest"},{"key":"2447_CR20","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1210\/jc.2017-02287","volume":"103","author":"M Hage","year":"2018","unstructured":"Hage M, Viengchareun S, Brunet E et al (2018) Genomic alterations and Complex Subclonal Architecture in sporadic GH-Secreting pituitary adenomas. J Clin Endocrinol Metab 103:1929\u20131939. https:\/\/doi.org\/10.1210\/jc.2017-02287","journal-title":"J Clin Endocrinol Metab"},{"key":"2447_CR21","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1210\/en.2013-1051","volume":"154","author":"T Lekva","year":"2013","unstructured":"Lekva T, Berg JP, Lyle R et al (2013) Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas. Endocrinology 154:3331\u20133343. https:\/\/doi.org\/10.1210\/en.2013-1051","journal-title":"Endocrinology"},{"key":"2447_CR22","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1126\/science.1077783","volume":"298","author":"EM Makarov","year":"2002","unstructured":"Makarov EM, Makarova OV, Urlaub H et al (2002) Small nuclear ribonucleoprotein remodeling during catalytic activation of the spliceosome. Science 298:2205\u20132208. https:\/\/doi.org\/10.1126\/science.1077783","journal-title":"Science"},{"key":"2447_CR23","doi-asserted-by":"publisher","first-page":"9176","DOI":"10.1128\/MCB.24.20.9176-9185.2004","volume":"24","author":"K-T Lin","year":"2004","unstructured":"Lin K-T, Lu R-M, Tarn W-Y (2004) The WW domain-containing proteins interact with the early spliceosome and participate in pre-mRNA splicing in vivo. Mol Cell Biol 24:9176\u20139185. https:\/\/doi.org\/10.1128\/MCB.24.20.9176-9185.2004","journal-title":"Mol Cell Biol"},{"key":"2447_CR24","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1523\/JNEUROSCI.5409-05.2006","volume":"26","author":"M Arango","year":"2006","unstructured":"Arango M, Holbert S, Zala D et al (2006) CA150 expression delays striatal cell death in overexpression and knock-in conditions for mutant huntingtin neurotoxicity. J Neurosci off J Soc Neurosci 26:4649\u20134659. https:\/\/doi.org\/10.1523\/JNEUROSCI.5409-05.2006","journal-title":"J Neurosci off J Soc Neurosci"},{"key":"2447_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1136\/jmg.2006.045153","volume":"44","author":"JM Andresen","year":"2007","unstructured":"Andresen JM, Gay\u00e1n J, Cherny SS et al (2007) Replication of twelve association studies for Huntington\u2019s disease residual age of onset in large Venezuelan kindreds. J Med Genet 44:44\u201350. https:\/\/doi.org\/10.1136\/jmg.2006.045153","journal-title":"J Med Genet"},{"key":"2447_CR26","doi-asserted-by":"publisher","first-page":"e0139812","DOI":"10.1371\/journal.pone.0139812","volume":"10","author":"M Montes","year":"2015","unstructured":"Montes M, Coiras M, Becerra S et al (2015) Functional consequences for apoptosis by transcription Elongation Regulator 1 (TCERG1)-Mediated Bcl-x and Fas\/CD95 Alternative Splicing. PLoS ONE 10:e0139812. https:\/\/doi.org\/10.1371\/journal.pone.0139812","journal-title":"PLoS ONE"},{"key":"2447_CR27","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1128\/MCB.06255-11","volume":"32","author":"M Montes","year":"2012","unstructured":"Montes M, Cloutier A, S\u00e1nchez-Hern\u00e1ndez N et al (2012) TCERG1 regulates alternative splicing of the Bcl-x gene by modulating the rate of RNA polymerase II transcription. Mol Cell Biol 32:751\u2013762. https:\/\/doi.org\/10.1128\/MCB.06255-11","journal-title":"Mol Cell Biol"},{"key":"2447_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.cell.2010.07.019","volume":"142","author":"MJ Moore","year":"2010","unstructured":"Moore MJ, Wang Q, Kennedy CJ, Silver PA (2010) An alternative splicing network links cell-cycle control to apoptosis. Cell 142:625\u2013636. https:\/\/doi.org\/10.1016\/j.cell.2010.07.019","journal-title":"Cell"},{"key":"2447_CR29","doi-asserted-by":"publisher","first-page":"16411","DOI":"10.1074\/jbc.M009256200","volume":"276","author":"DR Mercatante","year":"2001","unstructured":"Mercatante DR, Bortner CD, Cidlowski JA, Kole R (2001) Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. Analysis of apoptosis and cell death. J Biol Chem 276:16411\u201316417. https:\/\/doi.org\/10.1074\/jbc.M009256200","journal-title":"J Biol Chem"},{"key":"2447_CR30","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1038\/onc.2013.533","volume":"33","author":"S Oltean","year":"2014","unstructured":"Oltean S, Bates DO (2014) Hallmarks of alternative splicing in cancer. Oncogene 33:5311\u20135318. https:\/\/doi.org\/10.1038\/onc.2013.533","journal-title":"Oncogene"},{"key":"2447_CR31","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/jcb.25309","volume":"117","author":"NJ Miller","year":"2016","unstructured":"Miller NJ, Schick K, Timchenko N et al (2016) The glutamine-alanine repeat domain of TCERG1 is required for the inhibition of the growth arrest activity of C\/EBP\u03b1. J Cell Biochem 117:612\u2013620. https:\/\/doi.org\/10.1002\/jcb.25309","journal-title":"J Cell Biochem"},{"key":"2447_CR32","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/jcb.22391","volume":"109","author":"SL Banman","year":"2010","unstructured":"Banman SL, McFie PJ, Wilson HL, Roesler WJ (2010) Nuclear redistribution of TCERG1 is required for its ability to inhibit the transcriptional and anti-proliferative activities of C\/EBPalpha. J Cell Biochem 109:140\u2013151. https:\/\/doi.org\/10.1002\/jcb.22391","journal-title":"J Cell Biochem"},{"key":"2447_CR33","doi-asserted-by":"publisher","first-page":"959832","DOI":"10.3389\/fgene.2022.959832","volume":"13","author":"P Yang","year":"2022","unstructured":"Yang P, Liu H, Li Y et al (2022) Overexpression of TCERG1 as a prognostic marker in hepatocellular carcinoma: a TCGA data-based analysis. Front Genet 13:959832. https:\/\/doi.org\/10.3389\/fgene.2022.959832","journal-title":"Front Genet"},{"key":"2447_CR34","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1038\/s41598-017-03354-z","volume":"7","author":"J Wang","year":"2017","unstructured":"Wang J, Dumartin L, Mafficini A et al (2017) Splice variants as novel targets in pancreatic ductal adenocarcinoma. Sci Rep 7:2980. https:\/\/doi.org\/10.1038\/s41598-017-03354-z","journal-title":"Sci Rep"},{"key":"2447_CR35","doi-asserted-by":"publisher","first-page":"e2247","DOI":"10.1210\/clinem\/dgaa040","volume":"105","author":"P Marques","year":"2020","unstructured":"Marques P, Caimari F, Hern\u00e1ndez-Ram\u00edrez LC et al (2020) Significant benefits of AIP Testing and clinical screening in familial isolated and young-onset Pituitary tumors. J Clin Endocrinol Metab 105:e2247\u2013e2260. https:\/\/doi.org\/10.1210\/clinem\/dgaa040","journal-title":"J Clin Endocrinol Metab"},{"key":"2447_CR36","first-page":"2635","volume":"35","author":"W Jia","year":"2015","unstructured":"Jia W, Zhu J, Martin TA et al (2015) Epithelial-mesenchymal transition (EMT) markers in human pituitary adenomas indicate a clinical course. Anticancer Res 35:2635\u20132643","journal-title":"Anticancer Res"},{"key":"2447_CR37","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1210\/endo-82-2-342","volume":"82","author":"AH Tashjian","year":"1968","unstructured":"Tashjian AH, Yasumura Y, Levine L et al (1968) Establishment of clonal strains of rat pituitary tumor cells that secrete growth hormone. Endocrinology 82:342\u2013352. https:\/\/doi.org\/10.1210\/endo-82-2-342","journal-title":"Endocrinology"},{"key":"2447_CR38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s11102-019-01003-4","volume":"23","author":"Z Zhu","year":"2020","unstructured":"Zhu Z, Cui W, Zhu D et al (2020) Common tools for pituitary adenomas research: cell lines and primary cells. Pituitary 23:182\u2013188. https:\/\/doi.org\/10.1007\/s11102-019-01003-4","journal-title":"Pituitary"},{"key":"2447_CR39","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1210\/endo-114-6-2054","volume":"114","author":"FN Zeytin","year":"1984","unstructured":"Zeytin FN, Gick GG, Brazeau P et al (1984) Growth hormone (GH)-releasing factor does not regulate GH release or GH mRNA levels in GH3 cells. Endocrinology 114:2054\u20132059. https:\/\/doi.org\/10.1210\/endo-114-6-2054","journal-title":"Endocrinology"},{"key":"2447_CR40","doi-asserted-by":"publisher","first-page":"110520","DOI":"10.1016\/j.mce.2019.110520","volume":"496","author":"AD van den Brand","year":"2019","unstructured":"van den Brand AD, Rubinstein E, van den Berg M, van Duursen MBM (2019) GH3 and RC-4BC cell lines are not suitable as in vitro models to study prolactin modulation and AHR responsiveness in rat pituitary. Mol Cell Endocrinol 496:110520. https:\/\/doi.org\/10.1016\/j.mce.2019.110520","journal-title":"Mol Cell Endocrinol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02447-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02447-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02447-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T14:41:43Z","timestamp":1738334503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02447-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["2447"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02447-7","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"18 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants (IRB No. 4-2011-0740).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no conflicts of interest that could be perceived as prejudicing the impartiality of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}